UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24, 2006
DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
NEW JERSEY 0-19777 22-3103129
(State or other (Commission File (IRS Employer
jurisdiction of Number) Identification
incorporation) Number)
25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(Address of principal executive offices, including ZIP code)
(978) 657-7500
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Securities Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 - OTHER EVENTS.
DUSA Pharmaceuticals, Inc. (the "Company") issued a press release on February
24, 2006, attached to and made a part of this report as Exhibit 99, reporting
statistically significant interim results from its 80 patient, multi-center
Phase II clinical study of photodynamic therapy (PDT) in the treatment of mild
to moderate photo-damage (sun induced skin aging) of the face.
Except for historical information, this report contains certain forward-looking
statements that involve known and unknown risk and uncertainties, which may
cause actual results to differ materially from any future results, performance
or achievements expressed or implied by the statements made. These
forward-looking statements relate to the possibility that additional parameters
will reach statistical significance, belief concerning the usefulness of the
product, and intention to consult with third parties regarding future
development towards regulatory approval. Furthermore, the factors that may cause
differing results include the uncertainties of completion of this trial and
conducting new clinical trials, the regulatory approval process, the marketplace
acceptance of the Company's products, sufficient funding to conduct new trials,
product development risks, maintenance of the Company's patent portfolio,
reliance on third party manufacturers, and other risks identified in DUSA's SEC
filings from time to time.
ITEM 9.01 - FINANCIAL STATEMENT AND EXHIBITS.
Item No. Description
-------- -----------
99 Press Release, dated February 24, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DUSA PHARMACEUTICALS, INC.
Dated: February 24, 2006 By: /s/ D. Geoffrey Shulman
------------------------------
D. Geoffrey Shulman, MD, FRCPC
Chairman of the Board and Chief
Executive Officer
EXHIBIT INDEX
Item No. Description
-------- -----------
99 Press Release, dated February 24, 2006